Matthew H Kulke
Medical Oncology · Mainehealth
Credentials: · · · ·
History
- Until 1998
- Until 1995
Mass General Brigham Healthcare Center - Chestnut Hill
Research
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
New England Journal of Medicine · 2017 · 2,601 citations
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Review · Molecular Cancer · 2023 · 1,738 citations
The Lancet · 2016 · 986 citations
- CF
47 papers
38 papers
31 papers
26 papers
26 papers
- JS
25 papers
- JC
23 papers
23 papers
Grants
- 2011–2016
Molecular and Genetic Analysis of Neuroendocrine Tumor Risk and Survival
National Cancer Institute · R01
Contact PI · $2.4M · Dana-Farber Cancer Inst
- 2003–2008
Molecular Analysis of Esophageal Cancer Survival
National Cancer Institute · K23
Contact PI · $679.2K · Dana-Farber Cancer Inst
Clinical trials
- 2010–2018
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
- 2010–2017
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
- 2006–2009
Principal investigator · Completed · Phase 2
CASI pharmaceuticals, Inc.
- 2005–2010
Pemetrexed in Patients With Advanced Neuroendocrine Tumors
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute